Bioage Labs (FRA:Y7G) Moat Score: 3/10 (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:Y7G Bioage Labs Inc FRA:Y7G
12 GF Score
Price €9.06
! 3 Warning Signs
View Full Analysis

What is Bioage Labs Moat Score?

Bioage Labs FRA:Y7G -7.17% 12 Moat Score is 3 as of Aug. 13, 2026. GuruFocus rates FRA:Y7G with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,026 Drug Manufacturers companies, Bioage Labs ranks better than 86.06% on this metric.

Bioage Labs has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Bioage Labs has No Moat: Bioage Labs Inc has very weak competitive advantages. It lacks significant market share, brand strength, and customer loyalty. The company does not possess substantial intellectual property or regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bioage Labs might have No Moat - Very weak/transient advantages.

Bioage Labs  (FRA:Y7G) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bioage Labs Moat Score Related Terms

FRA:Y7G vs PCRX, ALVO, AMPH: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioage Labs Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's Moat Score distribution charts can be found below:

* The bar in red indicates where Bioage Labs's Moat Score falls into.


FRA:Y7G
12GF Score
Bioage Labs Inc FRA:Y7G
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Bioage Labs (FRA:Y7G) has a Moat Score of 3 as of Aug. 13, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Bioage Labs ranks #143 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Bioage Labs' Moat Score too high?
Bioage Labs' current Moat Score is 3. Based on the distribution chart, Bioage Labs ranks #143 out of 1026 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bioage Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioage Labs' Moat Score compare to PCRX and ALVO?
According to the Drug Manufacturers industry distribution chart, Bioage Labs ranks #143 out of 1026 companies for Moat Score. This places Bioage Labs in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Bioage Labs's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioage Labs stock overvalued right now?
Bioage Labs (FRA:Y7G) has a current Moat Score of 3. The current Moat Score is 3. Bioage Labs' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Bioage Labs (FRA:Y7G), the current Moat Score is 3 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioage Labs Business Description

Other Exchanges BIOA:USA
Address 1445A South 50th Street, Richmond, CA, USA, 94804
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
12GF Score

Get the complete analysis for FRA:Y7G

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.06
Price